Document Detail


High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome.
MedLine Citation:
PMID:  12006894     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
High creatinine kinase (CK) levels and leukocytosis are known to be associated with neuroleptic malignant syndrome (NMS). The authors sought to determine if their presence during non-NMS psychotic episodes is predictive of the later development of NMS. Sixteen psychotic inpatients who met the criteria for NMS were included. For statistical comparison, two control groups were formed by matching each study patient with two non-NMS patients for age, gender, ethnicity, and year and ward of hospitalization (n = 32). The maximal individual serum levels of CK, lactate dehydrogenase (LDH), serum glutamic oxaloacetic transaminase (SGOT), and white blood cell count (WBC) during all non-NMS psychotic episodes (Brief Psychiatric Rating Scale 40) were averaged. To normalize the distribution, the individual averages were transformed to natural logarithms (Ln). Mean Ln (average [CK]) in the patients with NMS was found to be 6.46 +/- 0.91 IU/L, and in the non-NMS patients, 5.24 +/- 0.90 IU/L (actual serum CK levels, 911 +/- 747 IU/L and 343 +/- 620 IU/L, respectively). This difference was statistically significant (F [2,15] = 10.5, p < 0.0001). In addition, CK levels above the upper limit of normal were noted in 76% of psychotic episodes in the patients with NMS and in only 30% of psychotic episodes in the non-NMS patients (p < 0.0001). There was no significant difference between the NMS and non-NMS groups in Ln(LDH), Ln(SGOT), or Ln(WBC) (F [2,15] = 1.4, 2.1, and 0.9, respectively). The authors concluded that high serum CK level during non-NMS psychotic episodes seems to be a risk factor for future NMS. Therefore, CK measurement may be justified on admission of acutely psychotic patients who have other risk factors and a history of psychosis-associated CKemia.
Authors:
Haggai Hermesh; Iris Manor; Roni Shiloh; Dov Aizenberg; Yoav Benjamini; Hanan Munitz; Abraham Weizman
Related Documents :
21183884 - Significance of in situ hybridization results for ebv-encoded rna in post-transplantati...
20556454 - Clinical observations on the significance of raised cardiac troponin-t in patients with...
9873934 - Studies on tumourous and other urogenital patients with respect to antigens of oncogeni...
9704684 - Serial creatinine kinase (ck) mb testing during the emergency department evaluation of ...
12615654 - Changes in propriospinally mediated excitation of upper limb motoneurons in stroke pati...
9548264 - Autonomic nervous system activity during infusion of l-arginine in patients with liver ...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  Journal of clinical psychopharmacology     Volume:  22     ISSN:  0271-0749     ISO Abbreviation:  J Clin Psychopharmacol     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-05-13     Completed Date:  2002-07-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8109496     Medline TA:  J Clin Psychopharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  252-6     Citation Subset:  IM    
Affiliation:
Geha Psychiatric Hospital and Felsenstein Medical Research Center, Petah Tiqva, Israel. hermesh@post.tau.ac.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Analysis of Variance
Case-Control Studies
Chi-Square Distribution
Creatine Kinase / blood*
Female
Humans
Leukocytes / enzymology
Male
Middle Aged
Neuroleptic Malignant Syndrome / blood*,  enzymology*,  psychology
Retrospective Studies
Risk Factors
Chemical
Reg. No./Substance:
EC 2.7.3.2/Creatine Kinase
Comments/Corrections
Comment In:
J Clin Psychopharmacol. 2003 Dec;23(6):668   [PMID:  14624200 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Antipsychotic-induced weight gain and therapeutic response: a differential association.
Next Document:  Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study.